APA (7th ed.) Citation

United States. Government Accountability Office. (2009). Brand-name prescription drug pricing: Lack of therapeutically equivalent drugs and limited competition may contribute to extraordinary price increases : report to congressionals requesters. U.S. Govt. Accountability Office.

Chicago Style (17th ed.) Citation

United States. Government Accountability Office. Brand-name Prescription Drug Pricing: Lack of Therapeutically Equivalent Drugs and Limited Competition May Contribute to Extraordinary Price Increases : Report to Congressionals Requesters. [Washington, D.C.]: U.S. Govt. Accountability Office, 2009.

MLA (9th ed.) Citation

United States. Government Accountability Office. Brand-name Prescription Drug Pricing: Lack of Therapeutically Equivalent Drugs and Limited Competition May Contribute to Extraordinary Price Increases : Report to Congressionals Requesters. U.S. Govt. Accountability Office, 2009.